Over-the-counter medicines could fail for Brits due to DNA
A staggering 99% showed a genetic variant that affects their sensitivity to certain medicines.
This could mean some drugs, including over-the-counter, everyday painkillers, antibiotics and other prescription medications, won't work for some people based on their individual DNA.
DNA could stop over-the-counter medicines working for some Brits
The blood test, part of Bupa's My Genomic Health scheme, also looked into their genetic risk of developing 36 preventable diseases, including cancers, heart conditions and type 2 diabetes.
It found 91% of participants were found to be at risk of developing a disease with genetic and lifestyle risk factors, such as fatty liver disease, breast cancer and certain heart diseases.
While 73% had multiple genetic variants that put them at raised risk of developing a condition that could be prevented or detected early, leading to better health outcomes, including the likes of high cholesterol, skin cancer and type 2 diabetes.
Of the participants, 49% were found to be carriers of a genetic variant that could lead to a raised risk of a certain condition in future generations.
How to get your own Medication Check
Following the successful pilot, Medication Check can now be purchased through Bupa and will also be available to more than three million of its customers as part of its workplace health scheme.
A saliva test will establish what medications are most likely to be effective, those with increased risk of adverse side effects, or ones that won't work for you at all.
When to see your GP about cancer
Dr Rebecca Rohrer, clinical innovation and genomics director for Bupa, said: 'We've long known that most medications only work for 30-50% of the population.
'However, this pilot has highlighted just how significantly individual genomes impact the effectiveness of medications in treating conditions.
'With more than half of us regularly taking a prescription medication and an increasing number affected by a chronic condition, it's crucial that people are prescribed the right medicine from the start, tailored to their unique genetic makeup.
'In the longer term, genomics is key to early detection and even preventing some illnesses altogether.'
Today is World Lung Cancer Day.
Contact your GP practice if you are experiencing any of these signs and symptoms of lung cancer.
It's probably nothing serious, but early diagnosis and treatment can save lives.
Find out more at https://t.co/YTftU8oZJO — NHS (@NHSuk) August 1, 2025
After completing the at-home medication check, patients will be offered a GP consultation with the healthcare provider to review any medication identified in their genetic tests.
It comes as Bupa is about to introduce two new products to its My Genomic Health suite later this year that will help to prevent or detect illness earlier.
The DNA Health Check will give people early warning of an increased genetic risk of four different conditions - breast cancer, prostate cancer, type 2 diabetes and cardiovascular disease.
While the Advanced DNA Health Check will combine insights from medication, disease risk, carrier status and traits, and will look at the genetic risk of developing conditions such as heart disease, metabolic disease and 10 types of cancer.
Recommended reading:
Carlos Jaureguizar, CEO for Bupa Global, India & UK, said: 'Whole genomic sequencing is fundamentally changing our approach to healthcare, pivoting from treatment to prevention.
'It has the power to become a health passport that people can reference throughout their lives.
'We firmly believe genomics is the path to health innovation and prevention, reducing the nation's health burden and giving people personalised knowledge of their own genomic profile to live well for longer.'
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Daily Mirror
4 minutes ago
- Daily Mirror
UK heatwave map shows exactly where in Britain faces scorching three-day 33C heat blast
As urgent weather warnings are put in place across parts of the UK, a new interactive map shows Brits whether or not their area will be affected by the fourth sweltering heatwave of summer 2025 High-level weather warnings are now in place across five areas of the UK as the nation faces the fourth heatwave of summer 2025. Temperatures are expected to soar into the mid-30s within the next 24 hours, with a heat health alert issued as of 9am this morning across London, the West Midlands, the East Midlands, the South East, and the East of England. As of yesterday (Monday, August 11), a total of 234 local areas were seeing heatwave conditions, with the warm blast spreading across most of England apart from areas in the North East and Cumbria, as well as coastal areas in the East and South. Now, an easy-to-use interactive map allows Brits to see whether or not their area will be affected. Check if your area is in heatwave conditions today by typing your postcode into the following interactive map: According to the official definition set by the Met Office, temperatures must have risen above 28C for three consecutive days for those areas to be experiencing a true heatwave. This means one sunny afternoon in the garden simply won't cut it. Interestingly, this definition differs across the country, with a slightly lower threshold of 27C in some parts of the South East, while this threshold drops again to just 25C in the South West of England, most of Wales, Northern England, Wales, and Northern Ireland. You can find out more about the Met Office's definitions of heatwave thresholds here. Temperatures approached 30C in various parts of the country yesterday, with areas of central and southern England set to meet heatwave criteria by midweek. The Met Office has warned that this latest wave will impact the health sector's capacity to deliver important services. The weather is expected to lead to "overheating" in indoor environments of community and care settings, as well as issues managing medicines. It's understood the sector is also bracing for staffing issues due to "external factors", including transport delays and increased power demand exceeding capacity. Dr Paul Coleman, Consultant in Public Health at the UK Health Security Agency, has issued the following statement: "Temperatures are forecast to rise above 30°C across central and southern parts of the country over the next few days, and generally hot weather is expected across most regions of England. "These kinds of temperatures can result in serious health outcomes across the population – particularly in those who are vulnerable, such as the elderly or those with serious health conditions - so it is important that everyone takes sensible precautions while enjoying the sun. "If you have friends, family or neighbours who are vulnerable, it is important to ensure they are aware of the forecasts and are following the necessary advice. Check in on them if you can to make sure they know that hot weather is on the way and how to keep themselves safe."
Powys County Times
6 minutes ago
- Powys County Times
Review launched over reports of delayed response to faulty knee replacement part
Health officials have launched a review amid reports that action was not taken swiftly enough following problems with a knee replacement part. BBC's File on 4 reported patients were left immobile and addicted to painkillers due to issues with the joint replacement. Some medics have said they first started noticing issues with a part of a knee replacement made by American medical device company Zimmer Biomet around eight years ago. A product recall was not issued until December 2022. A standard total knee replacement has four parts – a femoral component, tibial tray, patellar component and a polyethylene insert. Concerns were raised about the tibial part – also known as 'NexGen Stemmed Option Tibial Component' – as experts found the implant was linked to higher revision rates compared to other models when it was paired with certain other knee replacement components. A recall was led by the Medicines and Healthcare products Regulatory Agency (MHRA) in December 2022 after analysis of National Joint Registry data. Leading knee surgeon Professor Leela Biant said action was not taken quickly enough after problems arose. She told File on 4 that concerns were raised by herself and colleagues around eight years ago – five years before the product recall. 'The issue is their initial reluctance to acknowledge a problem and to not really engage with a process to evaluate these patients until they got to a situation where they had to,' she told the programme. In June 2022, a study was published in the journal Bone & Joint Open which suggested 'there is a fundamental issue with this NexGen implant design'. Patients have told the BBC about the impact on their lives. Debbie Booker, a manager for a company running retirement homes on the south coast, had a knee replacement operation at a local NHS hospital in 2016. Mrs Booker, from Southampton, described how it initially felt like the operation was a success but a year later she was suddenly 'in agony'. As a result of the pain she said she had to take powerful pain killers. 'I was on fentanyl and morphine. I was actually addicted to morphine and it took me a long time to actually come off the morphine because I was addicted,' she said. Medics found the implant had slipped out of place and she needed revision surgery. Another patient, known only as Diana, described how within three years of her left knee replacement surgery she went from being an active retiree to being sofa-bound. 'Every time I stood up I was standing on a broken leg and it was agony,' she told the programme. It also impacted surgeons who used the implant during their operations. One described how they became a surgical 'outlier', with higher revision rates than expected, after using the implant. File on 4 reported the implant had been used on 10,000 patients. Local NHS teams are responsible for reviewing and, where clinically necessary, replacing affected implants. A spokesperson for NHS England said: 'The safety of patients is the absolute priority for the NHS. 'Where issues are identified with any medical device, local NHS teams work swiftly to assess patients and provide replacement treatment where clinically necessary, in accordance with recommendations from the MHRA and device manufacturers. 'NHS England is currently reviewing the case involving Zimmer Biomet NexGen knee implants.' Zimmer Biomet said in a statement: 'Zimmer Biomet is committed to the highest standards of patient safety, quality, and transparency. 'We issued the Field Safety Notice (FSN) proactively and voluntarily, in consultation with the MHRA, after new UK National Joint Registry (NJR) data indicated the Stemmed Option tibial component was not performing as well when used in combination with two specific femoral components (LPS Flex Option and LPS Flex GSF Option) compared to other combinations of components for which the NJR holds data. 'The vast majority of patients had positive outcomes, and we acted swiftly and responsibly by removing the tibial component from the market to prevent future use in those combinations. 'Zimmer Biomet meets all relevant regulatory requirements and maintains a robust post-market surveillance program. 'All our products are approved in accordance with the relevant regulations, and we continuously monitor the performance of our products once they are available to surgeons. 'Patient safety, transparency, and clinical excellence remain our highest priorities.'
Glasgow Times
8 minutes ago
- Glasgow Times
Review launched over reports of delayed response to faulty knee replacement part
BBC's File on 4 reported patients were left immobile and addicted to painkillers due to issues with the joint replacement. Some medics have said they first started noticing issues with a part of a knee replacement made by American medical device company Zimmer Biomet around eight years ago. A product recall was not issued until December 2022. A standard total knee replacement has four parts – a femoral component, tibial tray, patellar component and a polyethylene insert. Concerns were raised about the tibial part – also known as 'NexGen Stemmed Option Tibial Component' – as experts found the implant was linked to higher revision rates compared to other models when it was paired with certain other knee replacement components. A recall was led by the Medicines and Healthcare products Regulatory Agency (MHRA) in December 2022 after analysis of National Joint Registry data. Leading knee surgeon Professor Leela Biant said action was not taken quickly enough after problems arose. She told File on 4 that concerns were raised by herself and colleagues around eight years ago – five years before the product recall. 'The issue is their initial reluctance to acknowledge a problem and to not really engage with a process to evaluate these patients until they got to a situation where they had to,' she told the programme. In June 2022, a study was published in the journal Bone & Joint Open which suggested 'there is a fundamental issue with this NexGen implant design'. Patients have told the BBC about the impact on their lives. Debbie Booker, a manager for a company running retirement homes on the south coast, had a knee replacement operation at a local NHS hospital in 2016. Mrs Booker, from Southampton, described how it initially felt like the operation was a success but a year later she was suddenly 'in agony'. As a result of the pain she said she had to take powerful pain killers. 'I was on fentanyl and morphine. I was actually addicted to morphine and it took me a long time to actually come off the morphine because I was addicted,' she said. Medics found the implant had slipped out of place and she needed revision surgery. Another patient, known only as Diana, described how within three years of her left knee replacement surgery she went from being an active retiree to being sofa-bound. 'Every time I stood up I was standing on a broken leg and it was agony,' she told the programme. It also impacted surgeons who used the implant during their operations. One described how they became a surgical 'outlier', with higher revision rates than expected, after using the implant. File on 4 reported the implant had been used on 10,000 patients. Local NHS teams are responsible for reviewing and, where clinically necessary, replacing affected implants. A spokesperson for NHS England said: 'The safety of patients is the absolute priority for the NHS. 'Where issues are identified with any medical device, local NHS teams work swiftly to assess patients and provide replacement treatment where clinically necessary, in accordance with recommendations from the MHRA and device manufacturers. 'NHS England is currently reviewing the case involving Zimmer Biomet NexGen knee implants.' Zimmer Biomet said in a statement: 'Zimmer Biomet is committed to the highest standards of patient safety, quality, and transparency. 'We issued the Field Safety Notice (FSN) proactively and voluntarily, in consultation with the MHRA, after new UK National Joint Registry (NJR) data indicated the Stemmed Option tibial component was not performing as well when used in combination with two specific femoral components (LPS Flex Option and LPS Flex GSF Option) compared to other combinations of components for which the NJR holds data. 'The vast majority of patients had positive outcomes, and we acted swiftly and responsibly by removing the tibial component from the market to prevent future use in those combinations. 'Zimmer Biomet meets all relevant regulatory requirements and maintains a robust post-market surveillance program. 'All our products are approved in accordance with the relevant regulations, and we continuously monitor the performance of our products once they are available to surgeons. 'Patient safety, transparency, and clinical excellence remain our highest priorities.'
